SuperworthCuranex Pharmaceuticals EPS CURX
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- −$7.60
- Latest quarter, Q2 FY26
- −$2.40
- Fiscal year 2025
- −$3.20
Curanex Pharmaceuticals' earnings per share was −$7.60 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.40.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.40 | n/a | −$7.60 | |
| Q1 FY26 | −$2.20 | n/a | −$5.20 | |
| Q4 FY25 | −$2.20 | n/a | −$3.20 | |
| Q3 FY25 | −$0.80 | n/a | n/a | |
| Q2 FY25 | $0.00 | n/a | n/a | |
| Q1 FY25 | −$0.20 | n/a | n/a | |
| Q3 FY24 | −$0.80 | n/a | n/a | |
| Q2 FY24 | −$0.40 | n/a | n/a | |
| Q1 FY24 | −$0.60 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Curanex Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CURXCuranex Pharmaceuticals | −$7.60 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.26 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Curanex Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.